|
1
|
Bosh FX, Ribes J and Borràs J:
Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taketomi A, Kitagawa D, Itoh S, Harimoto
N, Yamashita Y, Gion T, Shirabe K, Shimada M and Maehara Y: Trends
in morbidity and mortality after hepatic resection for
hepatocellular carcinoma: An institute's experience with 625
patients. J Am Coll Surg. 204:580–587. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vauthey JN, Lauwers GY, Esnaola NF, Do KA,
Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A,
et al: Simplified staging for hepatocellular carcinoma. J Clin
Oncol. 20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okuda K, Ohtsuki T, Obata H, Tomimatsu M,
Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K: Natural history of
hepatocellular carcinoma and prognosis in relation to treatment.
Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kudo M, Chung H and Osaki Y: Prognostic
staging system for hepatocellular carcinoma (CLIP score): Its value
and limitations, and a proposal for a new staging system, the Japan
Integrated Staging Score (JIS score). J Gastroenterol. 38:207–215.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
A new prognostic system for hepatocellular
carcinoma, . A retrospective study of 435 patients: The Cancer of
the Liver Italian Program (CLIP) investigators. Hepatology.
28:751–755. 1998.PubMed/NCBI
|
|
8
|
Leung TW, Tang AM, Zee B, Lau WY, Lai PB,
Leung KL, Lau JT, Yu SC and Johnson PJ: Construction of the Chinese
University Prognostic Index for hepatocellular carcinoma and
comparison with the TNM staging system, the Okuda staging system
and the Cancer of the Liver Italian Program staging system: A study
based on 926 patients. Cancer. 94:1760–1769. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Villa E, Colantoni A, Cammà C, Grottola A,
Buttafoco P, Gelmini R, Ferretti I and Manenti F: Estrogen receptor
classification for hepatocellular carcinoma: Comparison with
clinical staging systems. J Clin Oncol. 21:441–446. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Serag HB, Marrero JA, Rudoplph L and
Reddy KR: Diagnosis and treatment of hepatocellular carcinoma.
Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruix T and Llovet JM: Prognostic
prediction and treatment strategy in hepatocellular carcinoma.
Hepatology. 35:519–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ng KK, Vauthey JN, Pawlik TM, Lauwers GY,
Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney
DM, et al: Is hepatic resection for large and multinodular
hepatocellular carcinoma justified? Results from a
multi-institutional database. Ann Surg Oncol. 12:364–373. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hanazaki K, Kajikawa S, Shimozawa N,
Shimada K, Hiraguri M, Koide N, Adachi W and Amano J: Hepatic
resection for hepatocellular carcinomain diameter of >or =10 cm.
Hepatogastroenterology. 49:518–523. 2002.PubMed/NCBI
|
|
15
|
Poon RT, Fan ST and Wong J: Selection
criteria for hepatic resection in patients with large
hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll
Surg. 194:592–602. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Machuuli M, Hasegawa H and Yamazaki S:
Ulitrasonically guided subsegmentectomy. Surg Gynecol Obstet.
161:346–350. 1985.PubMed/NCBI
|
|
17
|
Hsieh CB, Yu CY, Tzao C, Chu HC, Chen TW,
Hsieh HF, Liu YC and Yu JC: Prediction of the risk of hepatic
failure in patients woth portal vein invasion hepatoma after
hepatic resection. Eur J Surg Oncol. 32:72–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roayaie S, Frischer JS, Emre SH, Fishbein
TM, Sheiner PA, Sung M, Miller CM and Schwartz ME: Long-term
results with multimodal adjuvant therapy and liver transplantation
for the treatment of hepatocellular carcinomas larger than 5
centimeters. Ann Surg. 235:533–539. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ueno K, Miyazono N, Inoue H, Nishida H,
Kanetsuki I and Nakajo M: Transcatheter arterial chemoembolization
therapy using iodized oil for patients with unresectable
hepatocellular carcinoma: Evaluation of three kinds of regimens and
analysis of prognostic factors. Cancer. 88:1574–1581. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee DS and Seong J: Radiotherapeutic
options for hepatocellular carcinoma with portal vein tumor
thrombosis. Liver Cancer. 3:18–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katamura Y, Aikata H, Kimura Y, Kawaoka T,
Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M,
et al: Intra-arterial 5-fluorouracil/interferon combination therapy
for hepatocellular carcinoma with portal vein tumor thrombosis and
extrahepatic metastases. J Gastroenterol Hepatol. 25:1117–1122.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang YH, Wu JC, Lui WY, Chau GY, Tsay SH,
Chiang JH, King KL, Huo TI, Chang FY and Lee SD: Prospective
case-controlled trial of adjuvant chemotherapy after resection of
hepatocellular carcinoma. World J Surg. 24:551–555. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolization or chemoembolization versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomized controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Suilleabhain CB, Poon RT, Yong JL, Ooi
GC, Tso WK and Fan ST: Factors predictive of 5-year survival after
transarterial chemoembolization for inoperable hepatocellular
carcinoma. Br J Surg. 90:325–331. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ono Y, Yoshimasu T, Ashikaga R, Inoue M,
Shindou H, Fuji K, Araki Y and Nishimura Y: Long-term results of
lipiodol-transcatheter arterial embolization with cisplatin or
doxorubicin for unresectable hepatocellular carcinoma. Am J Clin
Oncol. 23:564–568. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ono T, Yamanoi A, Nazmy EL, Assal O, Kohno
H and Nagasue N: Adjuvant chemotherapy after resection for
hepatocellular carcinoma causes deterioration of long-term
prognosis in cirrhotic patients: Metaanalysis of three randomized
controlled trials. Cancer. 91:2378–2385. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chao AO, Yuen MF, Hui CK, Tso WK and Lai
CL: A prospective study regarding the complication of transcatheter
intraarterial lipiodol chemoembolization in patients with
hepatocellular carcinoma. Cancer. 94:1747–1752. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC,
Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP and Hsieh CB: Comparing
hepatic resection and transarterial chemoembolization for Barcelona
Clinic Liver Cancer (BCLC) Stage B hepatocellular carcinoma: Change
for treatment of choice? World J Surg. 34:2155–2161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ho MC, Huang GT, Tsang YM, Lee PH, Chen
DS, Sheu JC and Chen CH: Liver resection improves the survival of
patients with multiple hepatocellular carcinomas. Ann Surg Oncol.
34:848–855. 2009. View Article : Google Scholar
|
|
31
|
Wang JH, Changchien CS, Hu TH, Lee CM, Kee
KM, Lin CY, Chen CL, Chen TY, Huang YJ and Lu SN: The efficacy of
treatment schedules according to Barcelona clinic liver cancer
staging for hepatocellular carcinoma-Survival analysis of 3892
patients. Eur J Cancer. 44:1000–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia HT, Guo GH, Huang XQ and Wang J:
Variations in serum level of cytokines associated with vascular
endothelial cells before and after treatment with either TACE and
liver resection in patients with hepatocellular carcinoma. Chin J
Hepatobiliary Surg. 1:23–26. 2012.
|
|
33
|
Lin CY, Kee KM, Wang JH, Lee CM, Chen CL,
Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, et al: Is the
cancer of the liver Italian program system an adequate weighting
for survival of hepatocellular carcinoma? Evaluation of intrascore
prognostic value among 36 subgroups. Liver Int. 29:74–81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
